Latest Conference Articles

2020 vision: The future of ophthalmology (Part IV)

2020 vision: The future of ophthalmology (Part IV)

September 22nd 2020

GLAUCOMA 360

In this fourth installment on "2020 vision," pharmaceutical representatives share their outlook on what lies ahead for glaucoma innovations within the ophthalmic space.

Minimizing inflammation post-cataract surgery

Minimizing inflammation post-cataract surgery

September 1st 2020

ARVO

Large randomized trial compares efficacy and safety of multiple regimens

Novel dexamethasone formulation shows efficacy and safety with once-daily use

Novel dexamethasone formulation shows efficacy and safety with once-daily use

September 1st 2020

ASCRS

A vehicle-controlled phase 2 study investigating once- and twice-daily administration of a novel, preservative-free topical formulation of dexamethasone as treatment for pain and inflammation after cataract surgery met its primary endpoints.

Looking to the future of retina innovations

Looking to the future of retina innovations

August 16th 2020

ASRS

Retina specialists Caesar Luo, MD, of Bay Area Retina Associates (Walnut Creek, CA) and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.

Image quality or depth of field — or both?

Image quality or depth of field — or both?

August 13th 2020

ASCRS

ICYMI: Alice Epitropoulos, MD, FACS, speaks on "Image quality or depth of field or both: Clinical outcomes from spherical aberration neutral monofocal toric IOL," during the 2020 ASCRS virtual meeting.

Evaluating 3-year recurrence rate in non-infectious posterior segment uveitis post-FAi

Evaluating 3-year recurrence rate in non-infectious posterior segment uveitis post-FAi

August 11th 2020

ASRS

Dilraj Grewal, MD, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during ASRS 2020.

Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)

Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)

August 4th 2020

ASRS

Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."

Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)

Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation (ASRS 2020)

August 3rd 2020

ASRS

Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

How one surgeon is integrating recent retina advances in COVID-19 (ASRS 2020)

How one surgeon is integrating recent retina advances in COVID-19 (ASRS 2020)

August 2nd 2020

ASRS

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

Diabetic retinopathy progression in anti-VEGF versus FA implant (ASRS 2020)

Diabetic retinopathy progression in anti-VEGF versus FA implant (ASRS 2020)

August 1st 2020

ASRS

Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.